Could Sars-Cov2 affect MS progression?

被引：14
作者：
Di Stadio, Arianna [1 ,2 ]
Romani, Luigina [3 ]
Bernitsas, Evanthia [4 ]
机构：
[1] Univ Perugia, Otolaryngol Dept, Perugia, Italy
[2] Queen Sq UCL Neurol, Neuroinflammat Lab, London, England
[3] Univ Perugia, Dept Expt Med, Perugia, Italy
[4] Wayne State Univ, Multiple Sclerosis Ctr, Detroit, MI USA
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 46卷
关键词：
COVID-19; Sars-CoV2 Multiple sclerosis; Inflammasomes; Microglia; Long-term sequela; NLRP3;
D O I：
10.1016/j.msard.2020.102540
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection.
引用
收藏
页数：2
相关论文
共 14 条
  • [1] COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination
    Boziki, Marina Kleopatra
    Mentis, Alexios-Fotios A.
    Shumilina, Maria
    Makshakov, Gleb
    Evdoshenko, Evgeniy
    Grigoriadis, Nikolaos
    [J]. BRAIN SCIENCES, 2020, 10 (06)
  • [2] Microglia polarization by mitochondrial metabolism modulation: A therapeutic opportunity in neurodegenerative diseases
    Di Stadio, Arianna
    Angelini, Corrado
    [J]. MITOCHONDRION, 2019, 46 : 334 - 336
  • [3] Targeting the NLRP3 Inflammasome in Severe COVID-19
    Freeman, Tracey L.
    Swartz, Talia H.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [4] Cytokines as Mediators of Neuroinflammation in Experimental Autoimmune Encephalomyelitis
    Gogoleva, V. S.
    Atretkhany, K. -S. N.
    Drutskaya, M. S.
    Mufazalov, I. A.
    Kruglov, A. A.
    Nedospasov, S. A.
    [J]. BIOCHEMISTRY-MOSCOW, 2018, 83 (09) : 1089 - 1103
  • [5] Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
    Govindarajan, Vaidya
    de Rivero Vaccari, Juan Pablo
    Keane, Robert W.
    [J]. JOURNAL OF NEUROINFLAMMATION, 2020, 17 (01)
  • [6] Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
    Guarda, Greta
    Braun, Marion
    Staehli, Francesco
    Tardivel, Aubry
    Mattmann, Chantal
    Foerster, Irmgard
    Farlik, Matthias
    Decker, Thomas
    Du Pasquier, Renaud A.
    Romero, Pedro
    Tschopp, Juerg
    [J]. IMMUNITY, 2011, 34 (02) : 213 - 223
  • [7] Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study
    Li, Yanli
    Shi, Jie
    Xia, Jianbo
    Duan, Jie
    Chen, Lijuan
    Yu, Xudong
    Lan, Weishun
    Ma, Quanfu
    Wu, Xufeng
    Yuan, Yichong
    Gong, Liyan
    Yang, Xinghai
    Gao, Han
    Wu, Chunchen
    [J]. FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [8] Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
    Merad, Miriam
    Martin, Jerome C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) : 355 - 362
  • [9] Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis
    Soares, Jaine L. S.
    Oliveira, Enedina M. L.
    Pontillo, Alessandra
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 26 - 34
  • [10] An Italian programme for COVID-19 infection in multiple sclerosis
    Sormani, Maria Pia
    [J]. LANCET NEUROLOGY, 2020, 19 (06) : 481 - 482
12